Clinical Trial Update: VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) [Phase 2]

View source ↗

Summary

Phase 2 trial of VB-111 in combination with nivolumab for metastatic colorectal cancer was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Colorectal Carcinoma

Drugs mentioned

• VB-111
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Metastatic Colorectal Cancer, Colorectal Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2023-06-09